Identification of Antiestrogen-Bound Estrogen Receptor α Interactomes in Hormone-Responsive Human Breast Cancer Cell Nuclei.
Valerio GigantinoAnnamaria SalvatiGiorgio GiuratoDomenico PalumboOriana StrianeseFrancesca RizzoRoberta TaralloTuula A NymanAlessandro WeiszGiovanni NassaPublished in: Proteomics (2020)
Estrogen receptor alpha (ERα) is a ligand-inducible transcription factor which mediates estrogen actions in hormone-responsive tumors and is targeted by effective anticancer therapies based on the ERα antagonist ligands, selective estrogen receptor modulators (such as Tamoxifen/TAM) or disruptors (such as Fulvestrant/ICI). Despite its importance for cancer therapy, including acquired resistance to endocrine therapy, the molecular basis of ERα response to different ligands is not fully known to date. Interaction proteomics shows great potential to identify and characterize molecular mechanisms of disease based on physical and functional protein-protein interaction networks. Tandem affinity purification coupled to mass spectrometry is applied here for mapping in hormone-responsive breast cancer cells nuclei, the ERα interactomes, induced by each of the two classes of antiestrogens. The results provide new insights on the molecular bases for antiestrogen-mediated control of ERα function and reveal new potential ways to overcome endocrine therapy resistance in cancer.
Keyphrases
- estrogen receptor
- cancer therapy
- mass spectrometry
- protein protein
- drug delivery
- small molecule
- transcription factor
- breast cancer cells
- high resolution
- endothelial cells
- squamous cell carcinoma
- physical activity
- liquid chromatography
- stem cells
- mesenchymal stem cells
- single cell
- papillary thyroid
- capillary electrophoresis
- cell therapy
- human health
- climate change
- high density
- smoking cessation